Final late-stage Clavis drug fails in Phase III
This article was originally published in Scrip
Executive Summary
Clavis Pharma's last great hope landed with a dull thud on 1 April when the Norwegian company said it is reviewing "strategic options" now that elacytarabine has failed to improve survival for patients with relapsed or refractory acute myeloid leukemia (AML) in the Phase III CLAVELA clinical trial.